Skip to main
RCKT
RCKT logo

Rocket Pharma (RCKT) Stock Forecast & Price Target

Rocket Pharma (RCKT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 38%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

Rocket Pharmaceuticals Inc. is advancing its late-stage gene therapy pipeline aimed at treating rare pediatric diseases, which positions the company for significant growth potential in the biopharmaceutical sector. The company's proactive engagement with the FDA, which is seen as a commitment to accelerate therapies for high unmet needs, suggests a favorable regulatory environment that could expedite the development and commercialization of its lead products. Additionally, the opportunity to refine trial parameters, such as adjusting patient enrollment for ongoing studies, underscores the likelihood of achieving important clinical milestones that may enhance shareholder value.

Bears say

The analysis of Rocket Pharmaceuticals Inc. presents significant concerns regarding its financial outlook based on the potential pricing strategies for its gene therapies. If gene therapy companies are restricted to pricing their one-time treatments in line with existing orphan drug prices, which typically reflect recurring use, this could negatively impact revenue expectations. Furthermore, the risks associated with immune toxicities from AAV delivery systems, alongside the uncertainty in clinical efficacy projections from preclinical models and historical data, further compound the potential for adverse financial implications.

Rocket Pharma (RCKT) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 38% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rocket Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rocket Pharma (RCKT) Forecast

Analysts have given Rocket Pharma (RCKT) a Buy based on their latest research and market trends.

According to 13 analysts, Rocket Pharma (RCKT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rocket Pharma (RCKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.